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INTRODUCTION
Over the last several years, my lab has been developing the Drosophila peripheral nerve as a system with which to identify and study the signalling pathways controlling growth of the perineurial (outer) glial layer (Yager et al., 2001) . The idea behind this approach is to apply the various molecular genetic methodologies uniquely available in Drosophila to enable us ultimately to identify all of the relevant genes that interact with NF1 to control growth, and place NF1 and these partner genes in as complete a mechanistic context as possible. Then this mechanism could be tested and refined in systems more similar to humans but more difficult to work with (i.e. the mouse). Because all of the experimentation is performed on the acutely dissected third instar larva, there are no complications or caveats associated with experimentation on cell culture systems, and we assay the entire nerve cross section as it exists within the whole organism. We thought that a more complete mechanistic understanding of growth control within peripheral nerves would greatly facilitate the ability to design drugs able to combat neurofibromas. Within this larger context, the specific research being performed under this grant was designed to test particular hypotheses that would increase this mechanistic understanding. The first task was designed to test the hypothesis that the amnesiac-encoded neuropeptide acts upstream, and Neurofibromin acts downstream, of a G protein subunit. The second task proposed additional experiments to test the hypothesis that perineurial glial growth is regulated by neurotransmitter release from motor neurons. The third aim was designed to test the possibility that the regulation of perineurial glial cell size and cell number could be mechanistically uncoupled. Successful completion of these aims would provide important information concerning the control of growth within peripheral nerves at the molecular level.
BODY
Task one: Does Neurofibromin act downstream of a G protein to control perineurial glial growth? In this task I proposed to test the hypothesis that perineurial glial growth is negatively regulated by the amnesiac (amn)-encoded neuropeptide acting through the G protein G a s, Neurofibromin and Pushover. Does G a s act downstream of the Amn neuropeptide to regulate perineurial glial growth? The most important experiment proposed in this task was to test the prediction that the perineurial glial growth-promoting effects of the amn X8 null mutation would be suppressed by expression of a constitutively active G a s called G a s*. However, we were stymied right at the outset of these experiments when we found that we could not obtain viable larvae carrying both UAS-G a s* and amn
X8
. When I reported this problem three years ago in my first annual report, I had no explanation for this phenomenon, but now we have the explanation: the amn X8 mutation, which was created by an imprecise excision of a P(GAL4) insertion into amn called amn 28a (Moore et al., 1998) , retains the fully functional GAL4 element that it inherited from its amn 28a parent. This fact was documented in my lab by both PCR (data not shown) and expression patterns and confirmed by colleagues in the field (Scott Waddell and Ulrike Heberlein, personal communication). The GAL4 within amn X8 is expressed in several hundred cells within the larval central nervous system and also within the ring gland (Caldwell et al., 2005) . This mutation is lethal in combination with many constitutively active, UAS-driven transgenes (data not shown), including G a s*, which makes this allele essentially useless for us.
Because amn X8 is the only known amn null mutation (Moore et al., 1998) , we couldn't choose another amn null mutation with which to replace amn
. Therefore we decided to remove the GAL4 element from amn X8 by passing amn X8 once again through P-element mediated transposition, and selecting for amn X8 -derivative chromosomes that had lost their lethality in combination with one of the UAS-driven, constitutively active transgenes (UAS-Ras V12 , in this case). I believe that we have obtained such an excision, and if verified by PCR, it will be back-crossed to our isogenic wildtype stock for isogenization and then introduced into gli-GAL4 for crossing to UAS-G a s* for analysis as described in the grant proposal. During the previous year, we have taken two approaches to test further these preliminary observations. First, we repeated most of the experiments described above to test reproducibility, increase the number of replicates, and increase the statistical significance of any positive result. Second, to rule out the possibility that any effect observed resulted from genetic background effects, rather than specific effects of transgenes, we are backcrossing at least five times all stocks carrying transgenes or mutations of interest to our isogenic wildtype stock, thus placing all experimental and control larvae in the same genetic background. Although most of the backcrossing is complete, measurements of perineurial glial thickness in these isogenized larvae is still in progress. Stock isogenization is essential for proper data collection in this system, because this system (particularly in a push mutant or Ras V12 -expressing background) appears to be exquisitely sensitive to genetic background effects. Andre Bernards, studying the role of NF1 in body size regulation, is also finding strong effects of genetic backgrounds. These effects might be the Drosophila equivalent of the well-known susceptibility to genetic modifiers of human patients with Neurofibromatosis.
When measurements on the same genotypes were repeated, we found that we could not reproduce some of the effects observed previously. In particular, we no longer observed a statistically significant effect of NF1 overexpression in combination with the strong Ras V12 (compare lanes #3 and #5 in Figure 2 below). This result suggests that NF1 overexpression does not hyperactivate the PKA pathway. This conclusion should by no means be taken to suggest that NF1 is not an intermediate in the PKA pathway. Genetic overexpression is not expected to confer any phenotype even for genes involved in particular processes if the amount of the gene product is not limiting. A more definitive result will come from the ability or inability of NF1 P2 to suppress the effects of Ras V12 in our isogenized lines. These larvae are currently under analysis.
In addition, the effects of overexpression of G a s* in combination with the weak Ras V12 (compare lanes #4 with lane #6 in Figure 1 below) also lost statistical significance. However, significant effects were still observed with overexpression of amn in combination with the weak Ras V12 (p=0.0094, compare lanes #4 and #5, Figure 1 below), and with overexpression of G a s* or amn with the strong Ras V12 (Figure 2 below, compare lane #3 with lanes #4 and #6). Most encouragingly for the hypothesis put forward above, overexpression of amn significantly enhanced the effects of the strong Ras V12 even in our isogenized lines (data not shown).
These observations suggest that the Amn-PKA hypothesis described above might still be true but I would like to perform the following experiments prior to publication to extend and confirm these observations. First, I note that from this observation, the somewhat surprising conclusion is that the source of Amn neuropeptide in the peripheral nerve is not the motor neuron, as anticipated, but rather the peripheral glia itself. This conclusion comes from the observation that the effects of amn overexpression are observed when amn is overexpressed in the peripheral glia. The amn neuropeptide released from the peripheral glia apparently acts cell autonomously on Amn receptors in the peripheral glia. Presumably, Amn is released from the peripheral glia as a result of increased peripheral glial [Ca 2+ ]; this increased [Ca 2+ ] might result from neurotransmitter released from the motor neuron acting on the peripheral glia. This potentially important observation needs to be confirmed with immunocytochemical methods; such experiments are currently underway but are beyond the scope of this grant. Second, we need to confirm these observations for transgenes overexpressing G a s* or PKA in isogenized lines. Third, we need to repeat the epistasis tests described above, particularly those involving NF1 P2 , in isogenized lines, which have mostly been constructed and are currently under analysis. If these results are similar to what we have observed in our non-isogenized lines, then our hypothesis will be proven. Fourth, I would like to identify the PKA-regulated step in the growth control pathway (e.g. does PKA activate growth via phosphorylation of Akt in the C terminus). This last step is beyond the scope of the current grant. Task two: Further tests of the hypothesis that increased neurotransmitter release from motor neurons (or increased neurotransmitter persistence) affects perineurial glial growth. We constructed and analyzed two of the fly lines that we proposed. These lines are: eag Sh; NF1 and eag; ine; NF1. In data reported in my first annual report, we found that perineurial glial growth was not significantly affected in each triple mutants compared to the double mutants assayed previously. Thus, we were not able to demonstrate that increased neurotransmitter signalling from the motor neurons activates perineurial glial growth. This year, we constructed the eag Sh; push triple mutant for analysis, as proposed in the statement of work. Unfortunately, the triple mutant is so sick that no larvae homozygous or hemizygous for each of the three mutations could be obtained, so no data from this genotype could be collected. So far, all of the data that we have managed to collect for this task has been negative: we have been unable to observed the specific increases in perineurial glial growth that we anticipated. Why? The hypothesis was based on the assumption that neuronal activity would affect the activity of Ras and its downstream effectors. Although this hypothesis has by no means been disproven, and tests of this hypothesis are still underway (described below), it is worthwhile at this point to begin to think of alternative hypotheses. Given our discovery that the growth-promoting effects of PI3 kinase overexpression are much stronger than the effects of Ras V12 overexpression (data obtained from my other DOD grant, to be reported in Lavery et al., in preparation), I would like to raise the possibility that neuronal activity is promoting PI3 kinase activity in a Ras-independent manner.
To begin to address this possibility, we successfully constructed flies carrying eag Sh and gli-GAL4 in an isogenized background. Now we will be able to cross flies from this line with flies carrying any UAS-driven transgenes, such as UAS-PKA* or UAS-Ras V12 , and measure glial thickness in larval progeny. This analysis will enable us to evaluate the effects on perineurial glial growth of activating specific peripheral glial-signalling pathways in a hyper-excitable larval background. In this way, we should be able to test the hypothesis that neuronal activity is necessary, but not sufficient, to activate the PI3 kinase pathway in a Ras-independent manner. Task three: Can perineurial glial growth be genetically uncoupled from perineurial glial proliferation? We counted the number of perineurial glial nuclei per length of nerve from several mutants exhibiting increased glial growth as well as their wildtype controls, as described in the statement of work. In my first annual report, I showed that expression of Ras V12 in the peripheral glia increased perineurial glial nuclear density by about 50%. This observation has been confirmed in larvae from isogenized fly lines: in fact, our final, publishable value is that Ras V12 expression in peripheral glia doubles perineurial glial nuclear density (see Figure 3 below ). This finding will be reported in Lavery et al. (in preparation) . Of even greater interest, we also found that in properly isogenized fly lines, the NF1 P2 null mutation also doubles the number of perineurial glial nuclei (Figure 3 ). It is possible that NF1 P2 increases perineurial glial nuclei number by activating Ras in the peripheral glia. We are currently constructing the fly stocks necessary to test if NF1 is required in the peripheral glia, or in other tissues, for proper control of nuclei number. We have successfully constructed isogenic ine push double mutant lines and are currently measuring nuclear density in this double mutant. We have evidence that Amn, G a s, and Neurofibromin activate PKA in Drosophila peripheral glia (Task One).
Our results for Task two were negative and there were no key research accomplishments.
We showed that expression of Ras V12 in the peripheral glia increases perineurial glial nuclear density (nuclei per mm of nerve). This result demonstrates that Ras V12 nonautonomously increases perineurial glial cell proliferation or recruitment of mesodermal precursors into the perineurium, as hypothesized (Task 3) We have found a similar phenotype in the NF1 P2 null mutant.
REPORTABLE OUTCOMES 1. Presentation entitled " Ras activity in peripheral glia promotes perineurial glial growth in Drosophila peripheral nerves", by James C. Yager, Alexander Rottgers, Michelle C. Wells, Elizabeth L. Carter and Michael Stern, was presented in a platform session at the NNFF International Consortium meeting, held at Aspen, CO, in June, 2003. Although not in evidence from the abstract title, during the first half of the talk I presented the data on interactions between Ras V12 and overexpression of amn and G a s* as described in the "Body" section above, under "Task one". CONCLUSIONS I report three major conclusions. First, I report that overexpression of amn enhances perineurial glial growth in larvae expressing Ras V12 . This effect is observed even with isogenized lines, demonstrating that this effect is due to the amn overexpression and not to a genetic background effect. A similar enhancement is observed with overexpression of G a s* and PKA. However these effects have not yet been tested with isogenized lines, so in these cases, the conclusion should be considered tentative. Taken together, these observations support the hypothesis that activation of the Amn-G a s -PKA pathway enhances the effects of Ras V12 on perineurial glial growth. These molecules could ultimately serve as targets for therapeutic manipulation of peripheral nerve growth. Currently we don't know how this pathway impinges on the Ras/Raf/PI3K pathway to regulate growth; our next task, which is beyond the scope of this current grant, will be to address these issues.
Second, we also provided evidence that the NF1 P2 null mutation suppresses the effects of Ras V12 , was epistatic to overexpression of amn in this suppression, but overexpression of PKA was epistatic to NF1 P2 for this effect (see Body of report, Task One, above). These effects have not yet been confirmed with isogenized lines, so these conclusions should be considered tentative. However, if these conclusions are finally proven, then these results would demonstrate that Neurofibromin has two, opposing roles in the regulation of perineurial glial growth. An understanding of the signals regulating the activity of Neurofibromin will not only add to our general knowledge of nerve growth control, but also improve our ability to select useful pharmacological agents for treatment.
Our third accomplishment is our demonstration under Task Three that in properly isogenized fly lines, the NF1 P2 mutation increases perineurial glial growth. Furthermore, larvae with peripheral glial expression of constitutively active Ras V12 also increase the number of perineurial glial cells. In my opinion, this is the best-supported and most important discovery of the grant: given that Ras V12 expression in the peripheral glia only modestly increases perineurial glial thickness, and because the NF1 P2 mutation has no significant effect on perineurial glial thickness (Yager et al., 2001 ; note that this measurement was performed in a different genetic background), these data confirm that mechanisms that regulate perineurial glial growth can be genetically uncoupled, at least in part, from mechanisms that regulate perineurial cell number. Drosophila peripheral nerves comprise a layer of motor and sensory axons, wrapped by an inner peripheral glia (analogous to the mammalian Schwann cell) and an outer perineurial glia (analogous to the mammalian perineurium). It was previously shown that perineurial glial growth in third instar Drosophila larvae is negatively regulated by a number of genes including push, which encodes a large Zn 2+ -finger-containing protein, amn, which encodes a putative neuropeptide, ine, which encodes a putative neurotransmitter transporter, and NF1. We show that mutations that reduce Ras activity suppress the increased perineurial glial thickness of the amn X8 deletion mutant and the ine; NF1 P2 and ine push double mutants. In contrast, expression of the constitutively active Ras V12 mutation specifically in the peripheral glia is sufficient to confer increased perineurial glial growth. We also show that the effect on perineurial glial growth of Ras V12 is significantly enhanced by mutations in push but not by mutations in ine or NF1. The push mutant, but not the ine or NF1 mutants, also exhibits hypersensitivity to low levels of Ras V12 expression. We conclude that Ras activity is both necessary and sufficient for increased perineurial glial growth, and that Ras can promote perineurial glial growth cellnonautonomously. We further suggest that mutations in NF1 and ine, but not push, increase perineurial glial growth by increasing [Ras-GTP] . Mutations in push could act on a pathway parallel to Ras, or increase Ras signalling independently of an effect on [Ras-GTP] . Cell nonautonomous effects of Ras activity could be responsible for the cellular heterogeneity of neurofibromas. Drosophila peripheral nerves comprise a layer of motor and sensory axons, wrapped by an inner peripheral glia (analogous to the mammalian Schwann cell) and an outer perineurial glia (analogous to the mammalian perineurium). We have been using these nerves as an assay platform to test the effects of mutations and transgenes on perineurial glial growth. It was previously shown that perineurial glial growth in third instar larval nerves is regulated by a number of genes including push, which encodes a large Zn 2+ -finger-containing protein, amn, which encodes a putative neuropeptide related to PACAP, and NF1. We found that expression of the constitutively active Ras V12 transgene specifically in peripheral glia increased growth within the perineurial glia. This result demonstrates that Ras activity is sufficient to promote perineurial glial growth, and that Ras can act cell nonautonomously. Surprisingly, we found that the NF1 P2 null mutation suppresses these effects of Ras V12 , suggesting that NF1 has a relevant activity that promotes, rather than inhibits, perineurial glial growth. The possibility that activation of adenylate cyclase represents this second activity is supported by the observation that expression within peripheral glia of any of three genes expected to increase protein kinase A (PKA) activity (a constitutively active PKA, the amn-encoded PACAP-like neuropeptide, or a constitutively active G a s) strongly enhances the growth promoting effects elicited by Ras V12 alone. These results are consistent with the possibility that a signalling pathway from the Amn neuropeptide through G a s, Neurofibromin, and PKA strongly potentiates the effectiveness of constitutive Ras activity on perineurial glial growth.
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ABSTRACT FORM
To identify the downstream components that mediate the effects of Ras, we tested the effects of constitutively active Raf and PI3 Kinase transgenes on perineurial glial growth. We found that expression of a constitutively active PI3 Kinase, but not a constitutively active Raf, strongly increased perineurial glial growth, suggesting the possibility that PI3 Kinase is an important mediator of the growth-promoting effects of Ras in peripheral nerves.
